Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma

Powles, T., Lackner, M.R., Oudard, S. et al. (18 more authors) (2016) Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma. JOURNAL OF CLINICAL ONCOLOGY, 34 (14). 1660-U204. ISSN 0732-183X

Abstract

Metadata

Authors/Creators:
  • Powles, T.
  • Lackner, M.R.
  • Oudard, S.
  • Escudier, B.
  • Ralph, C.
  • Brown, J.E.
  • Hawkins, R.E.
  • Castellano, D.
  • Rini, B.I.
  • Staehler, M.D.
  • Ravaud, A.
  • Lin, W.
  • O'Keeffe, B.
  • Wang, Y.
  • Lu, S.
  • Spoerke, J.M.
  • Huw, L-Y.
  • Byrtek, M.
  • Zhu, R.
  • Ware, J.A.
  • Motzer, R.J.
Copyright, Publisher and Additional Information: © 2016 American Society of Clinical Oncology. Reproduced in accordance with the publisher's self-archiving policy.
Keywords: apitolisib; everolimus; renal cell carcinoma; clinical trial
Dates:
  • Published: 10 May 2016
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Medicine (Sheffield) > Division of Genomic Medicine (Sheffield) > Department of Oncology (Sheffield)
The University of Sheffield > Sheffield Teaching Hospitals
Depositing User: Symplectic Sheffield
Date Deposited: 04 Jul 2016 12:54
Last Modified: 04 Jul 2016 12:54
Published Version: http://dx.doi.org/10.1200/JCO.2015.64.8808
Status: Published
Publisher: American Society of Clinical Oncology
Refereed: Yes
Identification Number: https://doi.org/10.1200/JCO.2015.64.8808
Related URLs:

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Share / Export

Statistics